Coexpression cluster:C802
From FANTOM5_SSTAR
Full id: C802_acute_Whole_chronic_blood_leukemia_Neutrophils_CD34
Phase1 CAGE Peaks
Hg19::chr11:58777262..58777273,- | p@chr11:58777262..58777273 - |
Hg19::chr12:54691726..54691738,- | p9@NFE2 |
Hg19::chr12:54694738..54694749,- | p5@NFE2 |
Hg19::chr12:54694758..54694805,- | p1@NFE2 |
Hg19::chr17:42466864..42466880,- | p1@ITGA2B |
Hg19::chr17:4835555..4835578,+ | p1@GP1BA |
Hg19::chr17:4835580..4835593,+ | p2@GP1BA |
Hg19::chr19:41856835..41856871,+ | p5@TMEM91 |
Hg19::chr1:207669613..207669634,+ | p3@CR1 |
Hg19::chr1:43803475..43803507,+ | p1@MPL |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
p.value | FDR | nGenes | nPathway | Name |
---|---|---|---|---|
0.000130420068097775 | 0.0275186343686305 | 2 | 85 | ECM-receptor interaction (KEGG):04512 |
5.62376772811216e-07 | 0.00032433580309358 | 3 | 88 | Hematopoietic cell lineage (KEGG):04640 |
1.02475767170167e-06 | 0.00032433580309358 | 4 | 466 | Hemostasis (Reactome):REACT_604 |
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0005887 | integral to plasma membrane | 0.000837617965512083 |
GO:0031226 | intrinsic to plasma membrane | 0.000837617965512083 |
GO:0007599 | hemostasis | 0.00259404803956199 |
GO:0044459 | plasma membrane part | 0.00259404803956199 |
GO:0050878 | regulation of body fluid levels | 0.00259404803956199 |
GO:0001850 | complement component C3a binding | 0.00259404803956199 |
GO:0001847 | opsonin receptor activity | 0.00259404803956199 |
GO:0004877 | complement component C3b receptor activity | 0.00259404803956199 |
GO:0004872 | receptor activity | 0.00495057300884679 |
GO:0001846 | opsonin binding | 0.00565907477652354 |
GO:0004875 | complement receptor activity | 0.00565907477652354 |
GO:0004871 | signal transducer activity | 0.00691583255524218 |
GO:0060089 | molecular transducer activity | 0.00691583255524218 |
GO:0005886 | plasma membrane | 0.00691583255524218 |
GO:0015057 | thrombin receptor activity | 0.00691583255524218 |
GO:0001848 | complement binding | 0.00777985356856844 |
GO:0042730 | fibrinolysis | 0.0109813829112646 |
GO:0009611 | response to wounding | 0.0118187531185448 |
GO:0030195 | negative regulation of blood coagulation | 0.0129256302981561 |
GO:0030193 | regulation of blood coagulation | 0.0129256302981561 |
GO:0004888 | transmembrane receptor activity | 0.0129256302981561 |
GO:0050819 | negative regulation of coagulation | 0.0141376950497417 |
GO:0050818 | regulation of coagulation | 0.0144236976063516 |
GO:0007166 | cell surface receptor linked signal transduction | 0.0188347888949068 |
GO:0009605 | response to external stimulus | 0.0188347888949068 |
GO:0030168 | platelet activation | 0.0199260400666217 |
GO:0006958 | complement activation, classical pathway | 0.0214868077403124 |
GO:0002455 | humoral immune response mediated by circulating immunoglobulin | 0.0221967666025441 |
GO:0047485 | protein N-terminus binding | 0.0260494934018146 |
GO:0006956 | complement activation | 0.0260494934018146 |
GO:0002541 | activation of plasma proteins during acute inflammatory response | 0.0260494934018146 |
GO:0016021 | integral to membrane | 0.0277034621720535 |
GO:0031224 | intrinsic to membrane | 0.0277034621720535 |
GO:0065008 | regulation of biological quality | 0.0283128582772092 |
GO:0016064 | immunoglobulin mediated immune response | 0.0283128582772092 |
GO:0022610 | biological adhesion | 0.0283128582772092 |
GO:0007155 | cell adhesion | 0.0283128582772092 |
GO:0019724 | B cell mediated immunity | 0.0283128582772092 |
GO:0008305 | integrin complex | 0.0291732855349702 |
GO:0004896 | hematopoietin/interferon-class (D200-domain) cytokine receptor activity | 0.0335055842626108 |
GO:0002253 | activation of immune response | 0.0335055842626108 |
GO:0002449 | lymphocyte mediated immunity | 0.0335055842626108 |
GO:0044425 | membrane part | 0.0335055842626108 |
GO:0006959 | humoral immune response | 0.0335055842626108 |
GO:0002250 | adaptive immune response | 0.0335055842626108 |
GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 0.0335055842626108 |
GO:0002443 | leukocyte mediated immunity | 0.0335055842626108 |
GO:0002526 | acute inflammatory response | 0.0335055842626108 |
GO:0032501 | multicellular organismal process | 0.0335055842626108 |
GO:0006950 | response to stress | 0.0335055842626108 |
GO:0050778 | positive regulation of immune response | 0.0335055842626108 |
GO:0007229 | integrin-mediated signaling pathway | 0.0335055842626108 |
GO:0002684 | positive regulation of immune system process | 0.0335055842626108 |
GO:0050776 | regulation of immune response | 0.036842459775197 |
GO:0002682 | regulation of immune system process | 0.036842459775197 |
GO:0007596 | blood coagulation | 0.036842459775197 |
GO:0050817 | coagulation | 0.0369156757555923 |
GO:0051240 | positive regulation of multicellular organismal process | 0.0373396381210043 |
GO:0043235 | receptor complex | 0.0378026624244675 |
GO:0002252 | immune effector process | 0.0378026624244675 |
GO:0045087 | innate immune response | 0.0385259798368652 |
GO:0042060 | wound healing | 0.0435130214904965 |
GO:0005515 | protein binding | 0.0435130214904965 |
GO:0001653 | peptide receptor activity | 0.0468444005596366 |
GO:0008528 | peptide receptor activity, G-protein coupled | 0.0468444005596366 |
GO:0008015 | blood circulation | 0.0490961773108645 |
GO:0003013 | circulatory system process | 0.0490961773108645 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|---|---|
myeloid cell | 2.26e-41 | 112 |
common myeloid progenitor | 2.26e-41 | 112 |
hematopoietic stem cell | 2.10e-35 | 172 |
angioblastic mesenchymal cell | 2.10e-35 | 172 |
hematopoietic oligopotent progenitor cell | 5.65e-34 | 165 |
hematopoietic multipotent progenitor cell | 5.65e-34 | 165 |
hematopoietic cell | 5.82e-32 | 182 |
myeloid leukocyte | 2.16e-27 | 76 |
myeloid lineage restricted progenitor cell | 8.15e-24 | 70 |
granulocyte monocyte progenitor cell | 3.36e-22 | 71 |
CD14-positive, CD16-negative classical monocyte | 5.58e-20 | 42 |
monopoietic cell | 5.85e-20 | 63 |
monocyte | 5.85e-20 | 63 |
monoblast | 5.85e-20 | 63 |
promonocyte | 5.85e-20 | 63 |
classical monocyte | 1.83e-19 | 45 |
leukocyte | 3.82e-19 | 140 |
macrophage dendritic cell progenitor | 4.72e-19 | 65 |
hematopoietic lineage restricted progenitor cell | 6.61e-18 | 124 |
nongranular leukocyte | 4.49e-16 | 119 |
connective tissue cell | 3.87e-08 | 365 |
mesenchymal cell | 1.08e-07 | 358 |
Ontology term | p-value | n |
---|---|---|
hemolymphoid system | 1.55e-25 | 112 |
hematopoietic system | 2.91e-25 | 102 |
blood island | 2.91e-25 | 102 |
bone marrow | 2.32e-20 | 80 |
immune system | 1.69e-19 | 115 |
bone element | 1.99e-18 | 86 |
skeletal element | 5.02e-15 | 101 |
skeletal system | 5.02e-15 | 101 |
lateral plate mesoderm | 2.34e-11 | 216 |
musculoskeletal system | 3.56e-08 | 167 |
adult organism | 4.57e-08 | 115 |
connective tissue | 5.48e-08 | 375 |
Ontology term | p-value | n |
---|---|---|
myeloid leukemia | 1.09e-17 | 31 |
leukemia | 1.94e-13 | 39 |
hematologic cancer | 3.12e-07 | 51 |
immune system cancer | 3.12e-07 | 51 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
{{{tfbs_overrepresentation_jaspar}}} |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
No analysis results for this cluster
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
This analysis result is provided for C0 - C305 clusters.